Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
View Patent ↗Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.
1. A single-stranded RNA molecule that mediates RNA interference against a target RNA, wherein said single-stranded RNA molecule comprises:
(a) a nucleic acid portion comprising a first nucleotide portion (N1) and a second nucleotide portion (N2) that are not self complementary, wherein said nucleic acid portion comprises at least 8 nucleotides that can base pair with a target site of the target RNA, and wherein the total number of nucleotides within the nucleic acid portion is from 8 to 26 nucleotides;
(b) an internal spacer portion, wherein said spacer portion comprises at least a first non-nucleotide spacer portion (S1) that covalently links the first and second nucleotide portions wherein said single-stranded RNA molecule comprises the following structure:
5′N1-S1-N2 3′
wherein:
(i) N1 contains either one nucleotide or a contiguous stretch of nucleotides;
(ii) S1 contains one or more non-nucleotide spacers covalently linking N1 and N2;
(iii) N2 contains either one nucleotide or a contiguous stretch of nucleotides;
(iv) S1 is at the 3′ end of N1 and at the 5′ end of N2; and
(v) wherein said single-stranded RNA molecule has one 3′ end; and
(c) a ligand.
2. The molecule of claim 1 , wherein S1 is an aliphatic or aromatic organic group.
3. The molecule of claim 2 , wherein S1 is a C 1 -C 12 alkyl chain that is optionally substituted.
4. The molecule of claim 3 , wherein said alkyl chain is optionally substituted with cholesterol.
5. The molecule of claim 2 , wherein S1 is selected from a group consisting of a C3 alkyl, a C6 alkyl, and polyethylene glycol.
6. The molecule of claim 1 , wherein N1 is 13 to 20 nucleotides long.
7. The molecule of claim 1 , wherein the total number of nucleotides within the nucleic acid portion is about 19 to about 21 nucleotides.
8. The molecule of claim 1 , wherein the target site is within a untranslated region of the target RNA.
9. The molecule of claim 8 , wherein the at least 8 nucleotides that can base pair with the target site is the whole or a part of a seed sequence of a naturally-occurring, endogenous miRNA nucleotide sequence.
10. The molecule of claim 9 , wherein S1 takes the place of from one to 4 internal nucleotides of the naturally-occurring, endogenous miRNA nucleotide sequence.
11. The molecule of claim 10 , wherein the nucleic acid portion of the molecule is at least 50% homologous to the naturally-occurring, endogenous miRNA nucleotide sequence.
12. The molecule of claim 1 , wherein the target site is within a gene coding region of the target RNA.
13. The molecule of claim 1 , wherein the nucleic acid portion of the molecule is at least 90% complementary to the target site.
14. The molecule of claim 1 , wherein the nucleic acid portion comprises at least 20 nucleotides that can base pair with the target site.
15. The molecule of claim 1 , wherein the nucleic acid portion further comprises a third nucleotide portion (N3) and the internal spacer portion further comprises a second non-nucleotide spacer portion (S2).
16. The molecule of claim 1 , wherein at least one nucleotide has a modified sugar.
17. The molecule of claim 1 , wherein at least one nucleotide has a modified internucleoside linkage.
18. The molecule of claim 1 , having a terminal cap at the 5′-end, the 3′-end, or both the 5′- and 3′-ends.
19. The molecule of claim 1 , wherein the ligand is a terminal group.
20. The molecule of claim 1 , wherein the ligand is a ligand for a cellular receptor.
21. The molecule of claim 20 , wherein the ligand is a carbohydrate.
22. The molecule of claim 21 , wherein the carbohydrate is an N-acetyl-D-galactosamine.
23. The molecule of claim 1 , wherein the ligand is attached by a linker.
24. A composition comprising the single-stranded RNA molecule of claim 1 and a pharmaceutically acceptable carrier.
25. The composition of claim 24 , further comprising a liposome, a hydrogel, a cyclodextrin, a biodegradable nanocapsule, a bioadhesive microsphere, or a proteinaceous vector.
26. A method of reducing the expression of an endogenous RNA target gene in a cell comprising administering a composition of claim 24 .